Addus HomeCare Co. (NASDAQ:ADUS – Get Free Report) CEO R Dirk Allison sold 12,500 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $123.16, for a total value of $1,539,500.00. Following the transaction, the chief executive officer now directly owns 141,897 shares in the company, valued at $17,476,034.52. This represents a 8.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Addus HomeCare Trading Down 2.5 %
Shares of NASDAQ:ADUS opened at $121.29 on Friday. Addus HomeCare Co. has a 12-month low of $85.43 and a 12-month high of $136.12. The business has a 50 day moving average of $127.69 and a two-hundred day moving average of $123.50. The company has a market capitalization of $2.20 billion, a PE ratio of 27.76, a PEG ratio of 2.15 and a beta of 1.04.
Addus HomeCare (NASDAQ:ADUS – Get Free Report) last posted its earnings results on Monday, November 4th. The company reported $1.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.28 by $0.02. Addus HomeCare had a net margin of 6.50% and a return on equity of 9.62%. The business had revenue of $289.80 million for the quarter, compared to analyst estimates of $289.42 million. During the same period in the prior year, the company posted $1.03 EPS. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. Equities research analysts predict that Addus HomeCare Co. will post 4.58 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Addus HomeCare
Analysts Set New Price Targets
A number of brokerages have issued reports on ADUS. Oppenheimer upped their price target on shares of Addus HomeCare from $140.00 to $145.00 and gave the company an “outperform” rating in a research note on Monday, September 23rd. TD Cowen upped their target price on Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. Macquarie reaffirmed an “outperform” rating and set a $139.00 price target on shares of Addus HomeCare in a research report on Monday, November 4th. KeyCorp initiated coverage on Addus HomeCare in a report on Friday, October 11th. They issued an “overweight” rating and a $150.00 price objective on the stock. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $136.00 target price on shares of Addus HomeCare in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $131.63.
Get Our Latest Analysis on Addus HomeCare
Addus HomeCare Company Profile
Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.
See Also
- Five stocks we like better than Addus HomeCare
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Dividend Capture Strategy: What You Need to Know
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Addus HomeCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Addus HomeCare and related companies with MarketBeat.com's FREE daily email newsletter.